Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TBXAS1 | P24557 | 14/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29004413 | 1.00 | TBXAS1 (1.00) | TBXAS1 | |
| SCHEMBL29004411 | 1.00 | TBXAS1 (1.00) | TBXAS1 | |
| SCHEMBL2532389 | 1.00 | TBXAS1 (1.00) | TBXAS1 | |
| SCHEMBL939851 | 1.00 | TBXAS1 (1.00) | TBXAS1 | |
| SCHEMBL1679410 | 1.00 | TBXAS1 (1.00) | TBXAS1 | |
| SCHEMBL285054 | 1.00 | TBXAS1 (1.00) | TBXAS1 | |
| SCHEMBL2533366 | 1.00 | TBXAS1 (1.00) | TBXAS1 | |
| SCHEMBL2535103 | 1.00 | TBXAS1 (1.00) | TBXAS1 | |
| SCHEMBL10247600 | 1.00 | TBXAS1 (1.00) | TBXAS1 | |
| SCHEMBL2531537 | 1.00 | TBXAS1 (1.00) | TBXAS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 73 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230378532-A1 | PolyElectrolyte Composition and Methods of Preparation Thereof | Kraton Corporation (US) | 2023-11-23 | — | — | US | claimed |
| EP-4280332-A1 | POLYELECTROLYTE COMPOSITION AND METHODS OF PREPARATION THEREOF | Kraton Polymers Nederland B.V. (NL) | 2023-11-22 | — | — | EP | claimed |
| CN-117080543-A | Polyelectrolyte composition and preparation method thereof | 科腾聚合物荷兰有限责任公司 | 2023-11-17 | — | — | CN | claimed |
| CN-114870818-A | Method for adsorbing and separating gold, platinum and palladium by utilizing polyion liquid gel adsorbent | 长春黄金研究院有限公司 | 2022-08-09 | — | — | CN | claimed |
| CN-114783641-A | Application method of polyion liquid gel material in uranium rhenium adsorption separation | 华中科技大学 | 2022-07-22 | — | — | CN | claimed |
| EP-2254858-B1 | PROCESS FOR PREPARING 2-AMINO-5-CYANOBENZOIC ACID DERIVATIVES | DU PONT (US) | 2016-09-28 | — | — | EP | claimed |
| US-8242279-B2 | Process for preparing 2-amino-5-cyanobenzoic acid derivatives | E. I. DU PONT DE NEMOURS AND COMPANY (US) | 2012-08-14 | — | — | US | claimed |
| US-20110003998-A1 | PROCESS FOR PREPARING 2-AMINO-5-CYANOBENZOIC ACID DERIVATIVES | E. I. DU PONT NEMOURS AND COMPANY | 2011-01-06 | — | — | US | claimed |
| EP-2254858-A1 | PROCESS FOR PREPARING 2-AMINO-5-CYANOBENZOIC ACID DERIVATIVES | E. I. du Pont de Nemours and Company (US) | 2010-12-01 | — | — | EP | claimed |
| WO-2009111553-A1 | PROCESS FOR PREPARING 2-AMINO-5-CYANOBENZOIC ACID DERIVATIVES | E. I. DU PONT DE NEMOURS AND COMPANY (US) | 2009-09-11 | — | — | WO | claimed |
| EP-0274867-A2 | Pharmaceutically active compounds | SCHERING CORPORATION (US) | 1988-07-20 | — | — | EP | claimed |
| US-11834452-B2 | CXCR7 antagonists | CHEMOCENTRYX, INC. (US) | 2023-12-05 | — | — | US | disclosed |
| US-20230378532-A1 | PolyElectrolyte Composition and Methods of Preparation Thereof | Kraton Corporation (US) | 2023-11-23 | — | — | US | disclosed |
| EP-4280332-A1 | POLYELECTROLYTE COMPOSITION AND METHODS OF PREPARATION THEREOF | Kraton Polymers Nederland B.V. (NL) | 2023-11-22 | — | — | EP | disclosed |
| CN-117080543-A | Polyelectrolyte composition and preparation method thereof | 科腾聚合物荷兰有限责任公司 | 2023-11-17 | — | — | CN | disclosed |
| EP-0560407-A1 | Pharmaceutically active compounds | SCHERING CORPORATION (US) | 1993-09-15 | — | — | EP | disclosed |
| WO-1991000858-A1 | PHARMACEUTICALLY ACTIVE COMPOUNDS | SCHERING CORPORATION (US) | 1991-01-24 | — | — | WO | disclosed |
| EP-0407217-A1 | Pharmaceutically active compounds | SCHERING CORPORATION (US) | 1991-01-09 | — | — | EP | disclosed |
| US-4851423-A | Pharmaceutically active compounds | SCHERING CORPORATION (US) | 1989-07-25 | — | — | US | disclosed |
| EP-0274867-A2 | Pharmaceutically active compounds | SCHERING CORPORATION (US) | 1988-07-20 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110003998-A1 | PROCESS FOR PREPARING 2-AMINO-5-CYANOBENZOIC ACID DERIVATIVES | C5, CBR3, C9 | TBXAS1 1045/4885 |
| US-11834452-B2 | CXCR7 antagonists | CXCR1, CXCR5, CCR7 | TBXAS1 606/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.